Impact of Pharmacists on Outcomes for Patients with Psychiatric or Neurologic Disorders
Overview
Authors
Affiliations
Introduction: Psychiatric and neurologic illnesses are highly prevalent and are often suboptimally treated. A 2015 review highlighted the value of psychiatric pharmacists in improving medication-related outcomes. There is a need to describe areas of expansion and strengthened evidence regarding pharmacist practice and patient care impact in psychiatric and neurologic settings since 2015.
Methods: A systematic search of literature published from January 2014 to June 2019 was conducted. Publications describing patient-level outcome results associated with pharmacist provision of care in a psychiatric/neurologic setting and/or in relation to central nervous system (CNS) medications were included.
Results: A total of 64 publications were included. There was significant heterogeneity of published study methods and data, prohibiting meta-analysis. Pharmacists practicing across a wide variety of health care settings with focus on CNS medication management significantly improved patient-level outcomes, such as medication adherence, disease control, and avoidance of hospitalization. The most common practice approach associated with significant improvement in patient-level outcomes was incorporation of psychiatric pharmacist input into the interprofessional health care team.
Discussion: Pharmacists who focus on psychiatric and neurologic disease improve outcomes for patients with these conditions. This is important in the current health care environment as most patients with psychiatric or neurologic conditions continue to have unmet needs. Additional studies designed to measure pharmacists' impact on patient-level outcomes are encouraged to strengthen these findings.
Hernandez Bustamante P, Charles A, Snider M, Catanzano S Ment Health Clin. 2025; 15(1):17-24.
PMID: 39974754 PMC: 11835365. DOI: 10.9740/mhc.2025.02.017.
Effectiveness of a pharmacist-led tele-psychiatric clinic in managing drug-related problems.
Al Shakhori M, Arain S, Abdulsalim S, Salim Karattuthodi M, Al Dhamen M, Almutairi S J Pharm Policy Pract. 2025; 18(1):2460038.
PMID: 39931673 PMC: 11809177. DOI: 10.1080/20523211.2025.2460038.
Stuhec M, Gazdag A, Cuk Z, Oravecz R, Batinic B Front Psychiatry. 2025; 15:1473832.
PMID: 39758448 PMC: 11695304. DOI: 10.3389/fpsyt.2024.1473832.
Wien K, Reissner P, Hefner G, Thern J, Borgwardt S Front Psychiatry. 2024; 15:1460098.
PMID: 39698211 PMC: 11652846. DOI: 10.3389/fpsyt.2024.1460098.
Standardized reporting on studies of psychiatric pharmacist interventions.
Parmentier B, Lister J, Moore T, Reinstatler K, Santos R, Payne G Ment Health Clin. 2024; 14(4):271-276.
PMID: 39104438 PMC: 11298031. DOI: 10.9740/mhc.2024.08.271.